PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AstraZeneca makes CinCor Pharma acquisition

The agreement involves access to global rights of blood pressure lowering therapy baxdrostat.

AstraZeneca (AZ) has agreed to acquire CinCor Pharma (CinCor) – a company that concentrates on developing novel treatments for hypertension and chronic kidney disease.

The addition of the company will increase AZ’s cardiorenal pipeline as it will include CinCor’s candidate drug, baxdrostat.

Baxdrostat is a selective, oral small-molecule inhibitor of aldosterone synthase – the enzyme responsible for the synthesis of aldosterone in the adrenal gland – and can be used for blood pressure lowering in treatment-resistant hypertension.

The drug represents a potentially leading next-generation aldosterone synthase inhibitor as it is selective for aldosterone synthase and, critically, spares the cortisol pathway among humans.

There is also potential for combining baxdrostat with Farxiga – a move that upholds AZ’s strategy to provide benefits throughout cardiorenal diseases, especially where there is a high unmet medical need.

Marc de Garidel, chief executive officer of CinCor, reflected: “We are excited about the proposed acquisition of CinCor by AZ as we believe it offers the prospect of accelerating the development timeline and expanding the breadth of benefits patients with cardiorenal diseases might obtain from baxdrostat, if approved.”

He added: “CinCor is committed to ensuring a smooth transition of the development responsibilities to AZ a once the acquisition is consummated.”

Mene Pangalos, executive vice president of BioPharmaceuticals R&D, AZ, concluded: “Acquiring CinCor supports our commitment to cardiorenal disease and further strengthens our pipeline with baxdrostat.

“Excess levels of aldosterone are associated with hypertension and several cardiorenal diseases, including chronic kidney disease and coronary artery disease, and being able to effectively reduce this would offer a much-needed treatment option for these patients.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026